Efficasy of Dapagliflozin in decreased blood glucose vs. Placebo in Kidney Transplant patients with diabetes before and after transplant: A Randomized Double-Blind Clinical Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20251125068105N1

Enrollment

Registered

2025-11-30

Start date

2026-03-03

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Transplant patients with diabetes before and after transplant. Kidney transplant status

Interventions

Intervention 1: Intervention group: The intervention group received 10 mg of the drug depagliflozin (Gludap) once a day. Intervention 2: Control group: The control group will take the placebo, prepare

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Diagnosis of type 2 diabetes before and after transplantation At least 6 months have passed since the kidney transplant. No active infection (urinary, vaginal, diabetic foot ulcer) No AKI in the past 30 days The transplant regimen has not changed in the past three months.

Exclusion criteria

Exclusion criteria: - History of severe reaction to dapagliflozin.

Design outcomes

Primary

Measure	Time frame
HbA1c. Timepoint: MONTHLY. Method of measurement: laboratory.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Ghaderi

Ahvaz University of Medical Sciences

armanghaderiofficial@gmail.com+98 61 3320 4501

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026